Krystal Biotech, Inc. $KRYS Shares Newly Bought by Inspire Investing LLC

Inspire Investing LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, Holdings Channel.com reports. The firm bought 1,581 shares of the company’s stock, valued at approximately $526,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Krystal Biotech during the second quarter valued at $1,554,113,000. William Blair Investment Management LLC acquired a new position in Krystal Biotech during the second quarter valued at $211,909,000. Jupiter Topco LLC purchased a new stake in Krystal Biotech in the 2nd quarter worth about $95,387,000. Bank of America Corp DE purchased a new stake in Krystal Biotech in the 2nd quarter worth about $95,308,000. Finally, First Trust Advisors LP boosted its position in Krystal Biotech by 42.9% during the 1st quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after acquiring an additional 105,245 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 2.4%

NASDAQ:KRYS opened at $332.29 on Friday. The firm’s fifty day simple moving average is $337.46 and its 200 day simple moving average is $308.68. The firm has a market capitalization of $9.84 billion, a PE ratio of 41.64 and a beta of 0.50. Krystal Biotech, Inc. has a 1 year low of $184.02 and a 1 year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 7.33 EPS for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of a number of research reports. Jefferies Financial Group reissued a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating and set a $361.00 price target on shares of Krystal Biotech in a research note on Thursday, October 15th. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an “outperform” rating and a $400.00 price target on the stock. Finally, Zacks Research downgraded shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $377.20.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.